Highlights

  • TrivarX Limited (ASX:TRI) says it has locked in supply of the stable isotope compound required to dose participants in the Phase 1 trial of its Stabl-IM imaging platform.
  • Stabl-IM uses stable isotope labelling and standard MRI to visualise actively replicating tumour cells without radioactive tracers or biopsy, targeting earlier detection of brain metastases.
  • TrivarX acquired the technology from Nucleics Pty Ltd, pivoting from its earlier mental-health and sleep diagnostics work built around an ECG-based platform and MEB-001.
  • The company has engaged boutique CRO Beyond Drug Development for an open-label Phase 1 safety study in healthy volunteers, targeted to begin before the end of CY2026.
  • Investors should watch trial commencement, regulatory pre-submissions in the US and EU, cash runway and conversion of milestones into performance-share triggers.

TrivarX Limited (ASX:TRI) has cleared one of the less glamorous but genuinely decisive hurdles standing between a laboratory concept and a first-in-human study: making sure it actually has the material to put into patients. The Perth-based health technology company says it has secured critical supply of the stable isotope compound that sits at the heart of Stabl-IM, its non-invasive brain-tumour imaging platform, allowing preparations for a Phase 1 clinical trial to move ahead.

For a small-cap medtech that only recently reinvented itself around Stabl-IM, the development matters more than it might first appear. A clinical trial cannot begin without a validated, clinical-grade supply of the agent being tested, and manufacturing scale-up is one of the most common reasons early trials slip. By locking down supply, TrivarX removes a tangible bottleneck and keeps alive its stated goal of dosing the first participants before the end of the 2026 calendar year.

What Has Happened

TrivarX has confirmed it has secured supply of the stable isotope compound used by Stabl-IM — the essential consumable administered to trial participants and then imaged using standard magnetic resonance imaging (MRI) machines. The company had previously flagged manufacturing scale-up and quality-control validation of its compounds as priority workstreams, and securing supply is the practical output of that effort.

The move follows a sequence of steps to build a clinical-stage business around the technology. TrivarX engaged boutique contract research organisation Beyond Drug Development to support its Phase 1 safety trial — an open-label, sequential-cohort study in healthy human volunteers using oral dosing, focused on safety and tolerability. The compound supply is what makes actually running such a study possible.

Management has framed the trial as a milestone event, with incoming chief executive Dr Danielle Meyrick emphasising a focus on commencing the study before the end of CY2026. Clinical protocol work, regulatory documentation and site selection have been underway in parallel.

Why It Matters

Every diagnostic agent that reaches a clinical trial must be manufactured to a standard suitable for use in humans, in reliable quantities. For Stabl-IM, which depends on a specific stable isotope-labelled compound, supply is a gating requirement, without which protocols, ethics approvals and site contracts have nothing to act on. Securing it de-risks the immediate path to the clinic and signals that the underlying chemistry can be produced and validated at the scale a trial demands — an early indicator the technology could eventually be manufactured at commercial volumes, alongside the regulatory pre-submission activities the company is running in the US and EU.

From Mental-Health Algorithms to Brain-Tumour Imaging

TrivarX has not always focused on oncology. It built its earlier identity in mental-health and sleep diagnostics, developing an artificial-intelligence-driven platform designed to detect Major Depressive Episodes from physiological signals such as ECG data, work associated with its MEB-001 program. The current TrivarX is a substantially repositioned business.

The pivot came in late 2025, when TrivarX moved to acquire the Stabl-IM intellectual property, expertise and supporting data from Australian biotechnology company Nucleics Pty Ltd. The market response was dramatic: TRI shares jumped around 136% on the day the deal was confirmed in October 2025, closing near A$0.026 after a previous close of around A$0.011.

How Stabl-IM Works

Stabl-IM uses stable isotope labelling to identify actively replicating cells within the brain. Because tumour cells divide rapidly, the labelled compound concentrates in areas of tumour activity, which can then be visualised using standard MRI equipment. Crucially, the company says the approach avoids radioactive tracers and surgical biopsy, positioning it as a safe and repeatable method. Standard MRI generally detects tumours only once they reach a few millimetres; TrivarX argues Stabl-IM could reveal replicating-cell activity earlier and allow tumour growth and treatment response to be monitored over time.

Brain metastases — cancers that spread to the brain from primary tumours elsewhere, most commonly lung and breast cancer — affect roughly one in five adult cancer patients, and outcomes after diagnosis remain poor. The company has pointed to a global neuro-oncology diagnostics market it estimates at around US$2.5 billion by 2030, and a brain-metastases treatment segment potentially reaching US$8.8 billion by 2035 — company-referenced projections rather than guarantees, but they frame the opportunity.

Key Financial and Operational Details

TrivarX funded its pivot through capital raising, securing roughly A$4.2 million via a two-tranche placement of about 525 million new shares at A$0.008 each, with JP Equity Partners as lead manager. Nucleics founder Dr Daniel Tillett, who is also managing director of Race Oncology (ASX:RAC), came in as a cornerstone investor with A$500,000, while directors committed a further A$200,000 subject to shareholder approval. A second tranche brought in around A$3.5 million to fund manufacturing scale-up, quality-control validation of the stable isotope compounds, and regulatory pre-submission activities.

The acquisition was structured as an exclusive option, with an upfront payment reported at around A$250,000 and performance shares — potentially up to 750 million issued to Nucleics — contingent on hitting Phase 1 and Phase 2 clinical milestones, tying much of the vendor's reward to future clinical success. As at late 2025 the company carried a market capitalisation of roughly A$19.6 million, a reminder that this remains a micro-cap developmental story. Key figures include chair David Trimboli, incoming CEO Dr Danielle Meyrick, and Dr Tillett as the technology's founder and continuing technical collaborator.

Potential Catalysts

The most immediate catalyst is commencement of the Phase 1 safety trial itself, targeted before the end of CY2026 and which the newly secured compound supply is designed to enable. Positive safety and tolerability data would be the next milestone.

Beyond the trial, regulatory pre-submissions in the US and EU and any expansion toward multi-site or patient studies could support the story. Achievement of defined clinical milestones would also trigger the performance-share arrangements tied to the Nucleics acquisition, which the market may read as objective markers of progress.

Material Risks and Uncertainties

The risks are considerable and typical of early-stage medtech. Stabl-IM has yet to be tested in humans, and a Phase 1 safety study is only the first of several hurdles; there is no guarantee it will demonstrate the safety, imaging precision or reproducibility the company hopes for. Regulatory pathways in multiple jurisdictions are lengthy, and imaging adoption depends on validation, clinician acceptance and reimbursement dynamics outside the company's control.

Financially, TrivarX is a pre-revenue micro-cap that will almost certainly need further capital, raising the prospect of dilution. It has recently pivoted its entire strategic focus, and execution risk around advancing an acquired, unproven technology is real. Market-size figures cited by the company are projections, not committed demand, and share-price reactions in a stock of this size can be volatile in both directions.

What Investors Should Watch Next

For TrivarX Limited (ASX:TRI), the near-term signposts are clear. The first is confirmation that the Phase 1 trial has formally commenced on the targeted timeline, now that supply of the stable isotope compound is in hand. The second is any safety and tolerability data as the sequential cohorts progress. The third is regulatory momentum — particularly pre-submission engagement in the US and EU. Investors should also watch the balance sheet and cash runway, given the near-certainty of future funding needs, and whether clinical milestones convert into the performance-share triggers embedded in the Nucleics deal.

Conclusion

Securing critical supply of its stable isotope compound is a practical, unglamorous but genuinely important step for TrivarX Limited (ASX:TRI). It addresses a common cause of delay for early-stage developers and keeps the company on track toward a first-in-human Phase 1 trial before the end of 2026. For a business that has reinvented itself around the Stabl-IM brain-tumour imaging platform, demonstrating it can supply the material its trial depends on is an early sign the technology can move from concept toward the clinic.

The caveats are equally clear: Stabl-IM remains unproven in humans, the regulatory road is long, and further funding will almost certainly be required. As with any micro-cap medtech, the gap between promise and commercial reality is wide. But by lining up supply, TrivarX has taken a concrete step to keep its neuro-oncology story moving — and the trial's commencement is now the milestone to watch.